Henry Schein (NASDAQ:HSIC) Upgraded by Wall Street Zen to Strong-Buy Rating

Wall Street Zen upgraded shares of Henry Schein (NASDAQ:HSIC) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday.

Other analysts have also recently issued research reports about the stock. Wells Fargo & Company increased their price target on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. Mizuho increased their price target on shares of Henry Schein from $81.00 to $88.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Weiss Ratings reiterated a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Barrington Research set a $97.00 price target on shares of Henry Schein and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Finally, BTIG Research started coverage on shares of Henry Schein in a research note on Thursday. They issued a “neutral” rating for the company. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $86.69.

Henry Schein Stock Up 2.1%

Henry Schein stock opened at $78.83 on Friday. The company has a market cap of $9.05 billion, a P/E ratio of 24.11, a price-to-earnings-growth ratio of 2.29 and a beta of 0.88. Henry Schein has a 1-year low of $61.94 and a 1-year high of $89.29. The company has a fifty day simple moving average of $76.91 and a 200 day simple moving average of $74.01. The company has a current ratio of 1.38, a quick ratio of 0.76 and a debt-to-equity ratio of 0.59.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.30 by $0.04. The business had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The firm’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.19 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Research analysts anticipate that Henry Schein will post 4.74 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Henry Schein news, EVP Mark E. Mlotek sold 5,925 shares of Henry Schein stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $80.80, for a total value of $478,740.00. Following the completion of the sale, the executive vice president owned 80,554 shares in the company, valued at $6,508,763.20. The trade was a 6.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Thomas C. Popeck sold 1,355 shares of Henry Schein stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $72.79, for a total transaction of $98,630.45. Following the completion of the sale, the chief executive officer owned 86,182 shares of the company’s stock, valued at $6,273,187.78. This trade represents a 1.55% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 105,911 shares of company stock worth $8,574,982. 1.08% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Henry Schein

Several hedge funds have recently bought and sold shares of the company. MAI Capital Management increased its holdings in Henry Schein by 7.5% in the 3rd quarter. MAI Capital Management now owns 2,061 shares of the company’s stock valued at $137,000 after buying an additional 144 shares during the period. Truist Financial Corp increased its holdings in Henry Schein by 3.3% in the 3rd quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock valued at $368,000 after buying an additional 175 shares during the period. HB Wealth Management LLC increased its holdings in Henry Schein by 1.3% in the 4th quarter. HB Wealth Management LLC now owns 15,034 shares of the company’s stock valued at $1,136,000 after buying an additional 191 shares during the period. Czech National Bank increased its holdings in Henry Schein by 0.8% in the 4th quarter. Czech National Bank now owns 26,386 shares of the company’s stock valued at $1,994,000 after buying an additional 206 shares during the period. Finally, Jain Global LLC increased its holdings in Henry Schein by 2.0% in the 3rd quarter. Jain Global LLC now owns 10,662 shares of the company’s stock valued at $708,000 after buying an additional 207 shares during the period. 96.62% of the stock is owned by institutional investors.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.